Advertisement
Singapore markets closed
  • Straits Times Index

    3,307.90
    -6.15 (-0.19%)
     
  • Nikkei

    38,719.35
    -227.58 (-0.58%)
     
  • Hang Seng

    19,278.62
    +58.00 (+0.30%)
     
  • FTSE 100

    8,416.45
    -7.75 (-0.09%)
     
  • Bitcoin USD

    70,003.06
    -1,230.87 (-1.73%)
     
  • CMC Crypto 200

    1,522.53
    +33.99 (+2.28%)
     
  • S&P 500

    5,321.41
    +13.28 (+0.25%)
     
  • Dow

    39,872.99
    +66.22 (+0.17%)
     
  • Nasdaq

    16,832.62
    +37.75 (+0.22%)
     
  • Gold

    2,421.20
    -4.70 (-0.19%)
     
  • Crude Oil

    79.06
    -0.20 (-0.25%)
     
  • 10-Yr Bond

    4.4140
    -0.0230 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,622.09
    -5.41 (-0.33%)
     
  • Jakarta Composite Index

    7,199.27
    +13.23 (+0.18%)
     
  • PSE Index

    6,613.60
    -20.06 (-0.30%)
     

Hyphens Pharma secures Asean license for psoriasis treatment Wynzora Cream

Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and additional fees.

Pharmaceutical and consumer healthcare group Hyphens Pharma International 1J5 has announced that its subsidiary Hyphens Pharma has entered into an agreement with MC2 Therapeutics for the exclusive rights to register and commercialise Wynzora Cream in the Asean region.

The exclusive licence, supply and commercialisation agreement for Wynzora, a leading topical treatment for plaque psoriasis, extends to all future product extensions and improvements of the product.

Hyphens will pay MC2 a total of EUR2.5 million ($3.6 million), which includes an upfront payment and fees upon reaching certain regulatory milestones. In addition, MC2 will be entitled to receive fees for sales milestones and double-digit royalties on net sales.

ADVERTISEMENT

MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation.

According to Hyphens, Wynzora is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate that has demonstrated high efficacy with quick improvement “within one week” for sufferers of psoriasis in clinical studies.

The medical product has been approved and marketed in key markets including Italy, Germany, Spain, the United Kingdom, and the United States.

“Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the Asean region. It has a clear ambition and strategy to grow its dermatology franchise and is an excellent partner for MC2 to leverage Wynzora in the region, a large and growing market with over 600 million people,” says MC2 CEO Jesper J. Lange.

“This deal substantiates our strategy to make Wynzora available to as many patients suffering from plaque psoriasis as possible globally, as we continue to develop and expand our pipeline of innovative first-in-class drug candidates within immunology and inflammation”, adds Lange.

Lim See Wah, CEO of Hyphens Pharma, says: “MC2’s commitment to develop novel treatment paradigms for skin diseases is synergistic with Hyphens’ presence and ambition to be a regional leader in Asean. Wynzora is a proven effective treatment for plaque psoriasis in the United States and Europe. Leveraging our strong regulatory and commercial capabilities, we will work closely with MC2 to accelerate the launch of Wynzora in the Asean region, which will benefit Asian patients suffering from psoriasis.”

The agreement will not have a material effect on the net tangible assets or earnings per share of Hyphens for the FY2024 ending Dec 31. 

Shares in Hyphens Pharma closed 1 cent lower or 3.45% down at 28 cents on March 12.

See Also: